Skip to content

Our Business

Shackelford Pharma Inc. is focused on developing, obtaining regulatory approval for, and commercializing drugs to address epilepsy.


Building on the pioneering work of Dr. Alan Shackelford and his treatment of over 25,000 patients to date, the company is developing epilepsy therapies targeting the endocannabinoid system of the human body. This system, only discovered in recent decades, may play a critical role in many important bodily functions and their dysfunction. The endocannabinoid system has been implicated in key neurological conditions such as seizures, headaches, and cognitive impairment.


Shackelford Pharma believes that it has an exciting opportunity to address high unmet medical needs by developing novel drugs, ultimately offering hope to millions of epileptic patients suffering with high unmet medical needs.

A world-class experienced team of entrepreneurs, scientists and pharmaceutical commercial personnel are backing Dr. Shackelford’s real-world clinical experience.

From Dr. Shackelford’s database, we have identified 30+ conditions that benefited from cannabinoid therapy. A thorough analysis was undertaking to narrow the list of conditions to those with the highest probability of commercial success. SPI's management has concluded that the best path forward is to concentrate in epilepsy with a focus on disorders with high unmet needs.


The company's first product under development, SP1707, was shown effective in treating a specific type of seizure in Dr. Shackelford's patient data as well as in pre-clinical animal testing. The company filed its foundational patent related to the use of SP1707 for the treatment of acute and chronic seizure disorders, either alone or as adjunctive therapy. This application included both supportive preclinical and clinical data.

Invest in Shackelford

Shackelford Pharma’s Regulation A Financing is now open. Investors are required to fill out the form below to begin the investment process.

Please check your JUNK/SPAM email folder if your invitation email from Dealmaker/Shackelford does not arrive in your inbox.

Invest Shackelford